41
Participants
Start Date
January 23, 2023
Primary Completion Date
March 4, 2025
Study Completion Date
March 4, 2025
RO7616789
RO7616789 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective part.
Tocilizumab
Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
Rigshospitalet, København Ø
Memorial Sloan Kettering Cancer Center, New York
University of Pittsburgh Medical Center, Pittsburgh
Georgetown Uni Medical Center, Washington D.C.
Fundacion Jimenez Diaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
SCRI Oncology Partners, Nashville
The Ohio State University Comprehensive Cancer Center, Columbus
Washington University School of Medicine, St Louis
Massachusetts General Hospital, Boston
Henry Ford Hospital, Detroit
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
The University of Texas MD Anderson Cancer Center, Houston
National Cancer Center Hospital East, Chiba
National Cancer Center Hospital, Tokyo
Uniwersyteckie Centrum Kliniczne, Gda?sk
Hospital Universitari Vall d'Hebron, Barcelona
Hoffmann-La Roche
INDUSTRY